Global Utilization And Registry Database for Improved preservAtion of doNor Livers
Launched by PARAGONIX TECHNOLOGIES · Oct 5, 2021
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
GUARDIAN-Liver is a post-market, observational registry of adult and pediatric liver transplant recipient patients whose donor liver was preserved and transported within the LIVERguard. The data is being collected retrospectively from medical records of patients already transplanted before the initiation of the registry and any new patients who meet the eligibility criteria.
About 1000 male and female subjects meeting the study inclusion and exclusion criteria will be enrolled into the study at about 20 clinical sites.
Candidates that fit the eligibility criteria and have had their donor ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Donor and donor liver matched to the recipient based upon institutional medical practice
- • Registered male or female primary liver transplant candidates
- Exclusion Criteria:
- • Donor and donor liver that do not meet institutional clinical requirements for transplantation
- • Living donors
- • Pediatric recipients (under 18)
About Paragonix Technologies
Paragonix Technologies is a pioneering medical device company specializing in advanced organ preservation solutions to enhance transplant outcomes. With a focus on innovative technologies, Paragonix develops cutting-edge systems that ensure the safe and efficient transport of donor organs, thereby improving the viability and success rates of transplants. Committed to transforming the field of transplantation, the company collaborates with healthcare professionals and institutions to deliver products that address critical challenges in organ preservation and transportation, ultimately aiming to save lives and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Birmingham, Alabama, United States
Stanford, California, United States
Durham, North Carolina, United States
Seattle, Washington, United States
Tampa, Florida, United States
Omaha, Nebraska, United States
Gainesville, Florida, United States
Patients applied
Trial Officials
Jason Vanatta, MD
Principal Investigator
Methodist Le Bonheur Healthcare
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials